NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.

NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.

Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.

Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.

People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.

Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.